Rxivist logo

Chemical control of a CRISPR-Cas9 acetyltransferase

By Jonathan H. Shrimp, Carissa Grose, Stephanie R. T. Widmeyer, Ajit Jadhav, Jordan L. Meier

Posted 16 Aug 2017
bioRxiv DOI: 10.1101/176875 (published DOI: 10.1021/acschembio.7b00883)

Lysine acetyltransferases (KATs) play a critical role in the regulation of transcription and other genomic functions. However, a persistent challenge is the development of assays capable of defining KAT activity directly in living cells. Towards this goal, here we report the application of a previously reported dCas9-p300 fusion as a transcriptional reporter of KAT activity. First we benchmark the activity of dCas9-p300 relative to other dCas9-based transcriptional activators, and demonstrate its compatibility with second generation short guide RNA architectures. Next, we repurpose this technology to rapidly identify small molecule inhibitors of acetylation-dependent gene expression. These studies validate a recently reported p300 inhibitor chemotype, and reveal a role for p300s bromodomain in dCas9-p300-mediated transcriptional activation. Comparison with other CRISPR-Cas9 transcriptional activators highlights the inherent ligand tuneable nature of dCas9-p300 fusions, suggesting new opportunities for orthogonal gene expression control. Overall, our studies highlight dCas9-p300 as a powerful tool for studying gene expression mechanisms in which acetylation plays a causal role, and provide a foundation for future applications requiring spatiotemporal control over acetylation at specific genomic loci.

Download data

  • Downloaded 982 times
  • Download rankings, all-time:
    • Site-wide: 27,072
    • In biochemistry: 619
  • Year to date:
    • Site-wide: 96,470
  • Since beginning of last month:
    • Site-wide: 85,786

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide